Carzelesin

Drug Profile

Carzelesin

Alternative Names: NSC D 619020; U 80244

Latest Information Update: 28 Nov 2000

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 28 Nov 2000 A phase II study has been added to the Cancer therapeutic trials section
  • 27 Oct 1998 Discontinued(II) for cancer in Europe
  • 06 Jan 1998 Discontinued-II for Breast cancer in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top